Skip to main content

Table 1 Clinico-pathological features of the study cases

From: Two histologically colorectal carcinomas subsets from the serrated pathway show different methylome signatures and diagnostic biomarkers

  Training set DNA validation set (pyrosequencing) RNA validation set (qPCR) Protein validation set (IHC)
SAC hmMSI-H   SAC hmMSI-H   SAC hmMSI-H   SAC hmMSI-H  
n = 39 (%) n = 9 (%) p value n = 16 (%) n = 9 (%) p value n = 19 (%) n = 22 (%) p value n = 26 (%) n = 21 (%) p value
Gender
 Female 20 (51.3) 7 (77.8)   8 (50) 7 (77.8)   15 (78.9) 14 (63.6)   19 (73.1) 12 (57.1)  
 Male 19 (48.7) 2 (22.2) 0.284 8 (50) 2 (22.2) 0.174 4 (21.1) 8 (36.4) 0.234 7 (26.9) 9 (42.9) 0.201
Age [SD] 71.6 [10.0] 66.4 [15.22] 0.094 72.0 [9.5] 70.3 [8.4] 0.267 69.0 [8.43] 69.75 [13.9] 0.839 69.9 [6.8] 70 [10.7] 0.969
Location
 Proximal 26 (66.7) 8 (100)   9 (56.3) 8 (88.9)   10 (52.6) 15 (68.2)   14 (53.8) 13 (61.9)  
 Distal/rectum 13 (33.3) 1 (0) 0.182 7 (43.8) 1 (11.1) 0.107 9 (47.4) 7 (31.8) 0.309 12 (46.2) 8 (38.1) 0.399
Dukes’ stage
 A 4 (10.3) 1 (11.1)   2 (12.5) 1 (11.1)   3 (15.8) 6 (27.3)   4 (15.4) 4 (19.0)  
 B 13 (33.3) 5 (55.6)   7 (43.8) 5 (55.6)   7 (36.8) 9 (40.9)   9 (34.6) 10 (47.6)  
 C 17 (43.6) 3 (33.3) 0.846 7 (43.8) 3 (33.3) 0.846 9 (47.4) 7 (31.8) 0.522 13 (50.0) 7 (33.3) 0.523
WHO grade
 High 5 (12.8) 0 (0)   1 (6.3) 0 (0)   1 (5.3) 0 (0)   0 (0) 0 (0)  
 Low 34 (87.2) 9 (100) 0.596 15 (93.8) 9 (100) 0.64 18 (94.7) 22 (100) 0.463 26 (100) 21 (100) NA
Type
 Non-mucinous 34 (87.1) 6 (66.7)   14 (87.5) 6 (66.7)   17 (89.5) 19 (86.4)   22 (84.6) 18 (85.7)  
 Mucinous 5 (12.8) 3 (33.3) 0.321 2 (12.5) 3 (33.3) 0.23 2 (10.5) 3 (13.6) 0.572 4 (15.4) 3 (14.3) 0.623
  1. SAC serrated adenocarcinoma, hmMSI-H colorectal carcinoma showing histological and molecular features of microsatellite instability, qPCR quantitative PCR, IHC immunohistochemistry, SD standard deviation